Markets

Puma (PBYI) Presents Favorable Phase II Data on Neratinib

A person taking notes from their tablet
Credit: Shutterstock photo

Puma Biotechnology, Inc.PBYI presented positive data from an investigator sponsored phase II study on neratinib in patients with HER2-mutated, non-amplified breast cancer. Data were presented at the annual meeting of the American Society of Clinical Oncology.

The primary endpoint of the study was the clinical benefit rate - defined as complete response (CR), partial response (PR) or stable disease (SD) greater than or equal to 6 months. While 14 patients had activating HER2 mutations, 2 patients had HER2 mutations of unknown significance among the 16 patients who were enrolled in the study.

Results showed that 5 patients achieved clinical benefit including 1 patient with a CR, 1 patient with a PR, and 3 patients with SD for greater than or equal to 6 months in the 14 patients with activating HER2 mutations. While the median duration of response in these 5 patients was 6 months, the median progression-free survival for all 14 patients was 5 months. No clinical benefit was observed with neratinib in the 2 patients who had HER2 mutations of unknown significance.

Moreover, the interim safety result showed that the most frequently observed adverse event was diarrhea.

We are encouraged by the phase II study results. Enrollment is currently underway in a cohort of patients receiving the combination of neratinib plus AstraZeneca's plc AZN Faslodex (fulvestrant). The company intends to present data from this cohort at a future medical meeting.

Meanwhile, Puma Biotech plans to seek approval for neratinib in the U.S. and EU in mid-2016 and in the second quarter of 2016, respectively. The company is looking to get neratinib approved for the extended adjuvant treatment of HER2-positive early stage breast cancer based on positive ExteNET phase III study results.

Given that Puma Biotech has no approved product in its portfolio at the moment and neratinib is its lead pipeline candidate, we expect investor focus to remain on updates pertaining to its development.

Puma Biotech is a Zacks Rank #3 (Hold) stock. A couple better-ranked stocks in the health care sector are ANI Pharmaceuticals, Inc. ANIP and Retrophin, Inc. RTRX , each sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

RETROPHIN INC (RTRX): Free Stock Analysis Report

PUMA BIOTECHNLG (PBYI): Free Stock Analysis Report

ANI PHARMACEUT (ANIP): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PBYI TVTX ANIP AZN

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More